Vitrolife AB (STO:VITR), an international medical device company, announced on Monday the decision by Barbro Fridén to step down as a member of the board of directors of the company, reportedly due to other future opportunities.
Fridén has been a member of the board of Vitrolife since 2010.
Vitrolife develops, produces and markets medical devices for assisted reproduction.
Headquartered in Gothenburg, Sweden, with offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, the UK and US, Vitrolife employs about 400 people and its products are sold in approximately 110 markets.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients